Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP raised its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 13.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,519,301 shares of the company’s stock after purchasing an additional 423,601 shares during the quarter. Wellington Management Group LLP owned about 5.45% of Stoke Therapeutics worth $115,152,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in Stoke Therapeutics by 19.7% during the first quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company’s stock worth $32,229,000 after purchasing an additional 162,797 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Stoke Therapeutics by 11.2% in the 1st quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company’s stock worth $52,456,000 after acquiring an additional 161,848 shares during the last quarter. Candriam S.C.A. raised its position in shares of Stoke Therapeutics by 12.4% during the first quarter. Candriam S.C.A. now owns 502,020 shares of the company’s stock worth $16,346,000 after purchasing an additional 55,330 shares during the period. Bank of America Corp DE lifted its holdings in shares of Stoke Therapeutics by 163.4% during the first quarter. Bank of America Corp DE now owns 543,095 shares of the company’s stock valued at $17,683,000 after purchasing an additional 336,931 shares during the last quarter. Finally, EcoR1 Capital LLC purchased a new stake in shares of Stoke Therapeutics during the first quarter valued at $3,256,000.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 7,176 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the transaction, the insider directly owned 20,422 shares in the company, valued at $593,054.88. This trade represents a 26.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Edward M. Md Kaye sold 12,567 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares of the company’s stock, valued at $3,989,560.71. This represents a 9.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 28,828 shares of company stock valued at $898,874 over the last three months. 9.60% of the stock is currently owned by insiders.

Stoke Therapeutics Stock Down 1.0%

STOK stock opened at $30.89 on Wednesday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -9.25 and a beta of 1.20. Stoke Therapeutics, Inc. has a 12 month low of $18.80 and a 12 month high of $40.22. The firm has a 50 day moving average of $31.22 and a two-hundred day moving average of $32.24.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. On average, research analysts expect that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on STOK shares. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a report on Friday, August 21st. They set an “overweight” rating and a $40.00 price objective on the stock. Guggenheim reissued a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. The Goldman Sachs Group began coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price target on the stock. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.